Pharmaceuticals

Repairing the Spine: Q&A with NervGen CEO Mike Kelly

bexib
By bexib 0 Min Read

Kelly explains how the company is taking a different approach to spinal cord injuries.

You Might Also Like

UMC Utrecht and VectorY Collaborate to Identify Biomarkers for ALS in New Study

FDA approves Merck’s Keytruda in combination with carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer

FDA grants new marketing authorization to Labcorp’s genomic testing kit

FDA Grants Accelerated Approval to Adaptimmune Therapeutics’ Tecelra for Adult Patients with Synovial Sarcoma Who Have Been Treated with Chemotherapy

Making Patient Data Actionable: Q&A with Noga Leviner

Share This Article
Previous Article TD is accepting applications for the 2024 TD Ready Challenge
Next Article Fintech funding: North American companies dominate first half investment
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Remembering Maker Faires in 2024?
Manufacturing
Top 5 Open Banking Stories of 2024
Banking
Ecommerce SEO Pros on AI, Strategies for 2025
Retail & E-commerce
Brintons launches first commercial carpet collection with V&A
Hospitality & Tourism